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Choline deficiency is associated with triacyiglycerol accumulation in the liver, and is the only nutritional state known 
to trigger hepatic cancer spontaneously. In two different experiments, rats were pair-fed for 6 weeks with control (0.2% 
choline), or choline-deficient (CD) (0.002% choline) diets. Hepatic holine and phosphocholine declined in CD animals 
to 54% and 16~ of control levels, respectively. In control livers, 1,2-sn-diacylglycerol (I,2-sn-DAG) concentration was 
(in nmol/g wet wt) 144 (+25; mean+SE); while in CD livers it was 792 (+ 140) in the first experiment. In the second 
experiment the values were 375 (+ 26) and 1147 (+ 74), respectively. 1,2-sn-DAG, aprecursor f triacylglycerol, is an 
endogenous activator of protein kinase C (PKC). PKC is the presumed site of action of the tumor-promoting phorbol 
esters. We suggest that he 1,2-sn-DAG accumulating i  CD liver could bind PKC, altering its activity, and thus contrib- 
ute to the carcinogenic effect of CD diets. 
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1. INTRODUCTION 
Choline deficiency is the only nutritional state 
which causes hepatic cancer by itself (i.e. in the 
absence of known carcinogenic agents). During 
choline deficiency, extremely large amounts of 
lipids (mainly triacylglycerol) accumulate in liver 
cells, eventually filling the entire hepatocyte [1]. 
Normally, triglycerides are secreted in very low 
density lipoproteins (VLDL), an essential compo- 
nent of which is phosphatidylcholine (PtdCho) 
[2-4]. In choline deficiency synthesis of  PtdCho is 
decreased and, in its absence, VLDL formation is 
compromised causing lipids to accumulate. 
Hepatocytes, prepared from choline-deficient rats 
(CD) were unable to secrete VLDL until choline or 
methionine was made available [4]. Ultrastructural 
abnormalities of the endoplasmic reticulum and 
Correspondence address: J.K. Biusztajn, Boston University 
School of Medicine, Room M1009, 85 East Newton Street, 
Boston, MA 02118, USA 
Golgi system, consistent with diminished VLDL 
transport, have been observed in electron 
microscopic studies of  hepatocytes from rats fed 
CD diet [5]. Triacylglycerol and glycerophospho- 
lipids (including PtdCho) are synthesized using 
1,2-sn-diacylglycerol (1,2-sn-DAG) as a precursor. 
In association with massive accumulation of 
triacylglycerol and with decreased synthesis of 
PtdCho, it is possible that 1,2-sn-DAG might ac- 
cumulate in CD liver. Indeed, total concentrations 
of  diglycerides (i.e. the sum of the 1,2- and the 
2,3-sn-diacylglycerols) have been previously found 
to increase 6-fold in the livers from rats fed CD, 
low-methionine diets for one week [6]. 
1,2-sn-DAG is also a second messenger, formed 
when plasma membrane receptors for certain hor- 
mones, neurotransmitters or growth factors are 
coupled to phospholipase C. The 1,2-sn-DAG 
molecule remains within the membrane after 
hydrolysis of phospholipids, and can activate a
regulatory enzyme, protein kinase C (PKC) [7]. 
During activation, which requires the presence of 
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calcium and phosphatidylserine, PKC is translo- 
cated from the cytosol to the plasma membrane 
[7,8]. 1,2-sn-DAG markedly increases the affinity 
of PKC for calcium, thereby activating the enzyme 
without a net increase in intracellular calcium con- 
centration [7]. 1,2-sn-DAG containing unsaturated 
fatty acids are the most potent in this respect, while 
1,3- or 2,3-sn-DAG neither activates nor inhibits 
the enzyme [7]. This means that the 2,3-sn-DAG 
liberated from triglyceride by the action of lipo- 
protein lipase, and heparin-released hepatic lipase 
will not activate PKC [7]. The appearance of 
1,2-sn-DAG in membranes i usually transient, 
and therefore PKC is activated only for a short 
time after a receptor has been stimulated. Tumor- 
promoting phorbo[ esters have higher affinity than 
1,2-sn-DAG for the same site on PKC; they cause 
translocation tomembranes and longer-lasting ac- 
tivation [7]. Prolonged activation of PKC by these 
compounds leads to down-regulation f the en- 
zyme (i.e. proteolysis to a form which is not bound 
to the membrane [7]). It is believed that the car- 
cinogenic effects of phorbol esters may be ex- 
plained by their interactions with PKC (though it 
is not clear whether activation or down-regulation 
is more important in this regard). If this is true 
then - in situations with prolonged and/or abnor- 
mally high concentrations - 1,2-sn-DAG might act 
as an endogenous tumor promoter. We report hat 
large amounts of 1,2-sn-DAG accumulate in CD 
livers. We propose that this 1,2-sn-DAG may cause 
a long-term alteration of hepatic PKC activity and 
thus act as an endogenous tumor promoter con- 
tributing to the carcinogenic effect of choline defi- 
ciency upon liver. 
2. MATERIALS AND METHODS 
In two experiments, Sprague-Dawlcy rats (150 g males), were 
pair-fed for 6 weeks with a semisynthetic diet (ICN Nutritional 
Biochemicals custom control diet: 10~0 casein, 10% a-soy pro- 
tein, 20% lard, 56% sucrose, 4% salt mix W, ICN vitamin mix; 
the control diet contained 0.2% choline bitartrate). The CD diet 
omitted choline bitartrate and contained 0.002~0 choline by our 
assay. Animals were anesthetized with nembutal and the livers 
were collected by freeze-clamping between tongs cooled in 
liquid nitrogen. Tissue samples were pulverized under liquid 
nitrogen using a mortar and pestle, forming a homogeneous 
powder. The powders were extracted according to the method 
of Blight and Dyer [9], and 1,2-sn-DAG content in the organic 
portion of the extract was determined using the method of 
Priess et al. [10]. This procedure utilizes 1,2-sn-DAG kinase, 
purified from E. coli (Lipidex Inc., Westfield, N J), and 
[-y-32p]ATP to form radiolabelled phosphatidic acid, which is 
isolated by thin-layer chromatography and its radioactivity 
determined by liquid scintillation spectrometry. This assay is 
specific for 1,2-sn-DAG and does not detect other isomers. 
Since large amounts of triglycerides are present in the extracts 
of CD livers, we added several control samples containing 
triolein to our 1,2-sn-DAG assay. No detectable [32p]phospha- 
tidic acid was formed during the assay of those samples. 
Choline and phosphocholine, were measured in an aliquot of 
the aqueous portion of the extracts. Approximately 4000 dpm 
of ~4C-labeled standards ([methyl-14C]choline chloride and 
[methyl-14C]phosphocholine from New England Nuclear, 
Boston, MA) were added to permit detection of eluted peaks us- 
ing an on-line radioactivity monitor after separation by high- 
pressure liquid chromatography (HPLC). In addition, internal 
standards labeled with stable isotopes were added to permit 
calculation of and correction for recovery during the assay 
[[15N]choline chloride, phosphocholine-d9 chloride (N,N,N- 
trimethyl-d9; barium salt; MSD Isotopes, Merck Chemical 
Division, St. Louis, MO), the amount for each was equivalent 
to approximately 10% of the amount normally found in that 
tissue]. Hepatic holine and phosphocholine w re purified from 
the aqueous phase of the extract by HPLC. The chromato- 
graphic conditions were based on the method described [11]. 
We used a normal phase column (Pecosphere-3C Si, 4.6 x 
83 mm; Perkin-Elmer, Norwalk, CT) and the elution was with 
a binary nonlinear gradient of acetonitrile/ethanol/acetic 
ac id / l .0M ammonium acetate/water/0.1 M sodium phos- 
phate (weak mobile phase: 800: 68 : 2: 3 : 127 : 10; strong mobile 
phase: 400:68:44:88:400:10) at a flow rate of 1.5 ml/min. 
Choline and phosphocholine, were collected and then the latter 
was hydrolyzed with 6 M HC1 at 80°C for 24 h to form free 
choline. The chloroform phase of the extracted tissue was used 
to assay the organic metabolites of choline. PtdCho and lyso- 
PtdCho were purified by thin-layer chromatography and then 
hydrolyzed in 6 M methanolic-HCl at 80°C for 60 rain, 
liberating choline. A volatile derivative of choline (demethyla- 
tion with benzenethiolate nd formation of propionyl ester) was 
then purified using gas chromatography (6 f tx  2 mm i.d. glass 
column packed with 3% OV-17 on GC22 precoated with 1% 
4-dodecyldiethylenetriamine succinamide) and measured with a 
mass selective detector (MSD; Hewlett Packard 5970 GC/MSD) 
[12]. Use of internal standards allowed correction for recovery 
of losses during the isolation procedures. Protein was determin- 
ed using the method of Bradford [13]. 
3. RESULTS AND DISCUSSION 
Choline-deficient rats had fatty infiltration of 
the liver, with obvious hepatic abnormalities visi- 
ble at the light microscopic level. The amount of 
protein in the livers of control animals was higher 
(142.8 _+ 0.01 mg/g) than in livers of CD (138.8 + 
0.004 mg/g). Choline and phosphocholine levels 
declined in CD livers to 54°7o and 16°70 of those of 
controls, respectively (table 1). There were no 
significant changes in hepatic PtdCho or lysoPtd- 
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Table 1 
Effect of  choline deficiency on choline and phosphocholine in 
rat liver 
Choline Phosphocholine 
(nmol/g wet wt) (nmol/g wet wt) 
Control 81 + 9.9 1417 + 356 
Deficient 44 + 4.2 230 + 58 
p = 0.03 p = 0.01 
Rats were pair-fed control or choline-deficient diets for 6 
weeks. Hepatic choline and phosphocholine were measured by 
gas-chromatography mass-spectrometry after purification by 
high-performance liquid chromatography. Results are 
expressed as means + SE (n = 3/group). Statistical significance 
of  differences between groups was ¢fetermined by t-test 
Cho concentrations. 1,2-sn-DAG concentrations 
increased 3-5-fold in CD liver compared to con- 
trol tissues in two separate xperiments (table 2). 
1,2-sn-DAG levels in control ivers were in agree- 
ment with those observed in normal isolated 
hepatocytes [10]. It has been reported that the sum 
of 1,2-sn-DAG and 2,3-sn-DAG increased from 
300 to 1800 nmol/g in rat liver after one week of 
choline deficiency [6]. Unfortunately, at the time 
of these investigations, no convenient technique 
existed to measure 1,2-sn-DAG specifically. Re- 
cent studies indicate that the physiological state of 
the cell determines the ratio of 1,2-sn-DAG to 
2,3-sn-DAG. For example in the parotid, 2,3-sn- 
DAG constituted approximately 8070 of DAG at 
rest, and stimulation of H-receptors specifically in- 
creased the formation of 2,3-sn-DAG, such that it 
constituted over 30o70 of the total DAG [14]. This 
2,3-sn-DAG was ineffective instimulating PKC ac- 
Table 2 
Effect of  choline deficiency on 1,2-sn-diacylglycerol in rat liver 
1,2-sn-Diacylglycerol 
(nmol/g wet wt) 
Expt I Expt II 
Control 144 + 25 375 + 26 
Deficient 792 + 140 1174 + 74 
p = 0.02 p = 0.0001 
Rats were pair-fed control or choline-deficient diets for 6 weeks 
in two separate xperiments. Hepatic 1,2-sn-diacylglycerol was 
measured by a radioenzymatic assay. Results are expressed as 
means + SE (n ffi 3/group in expt I; and n = 9-10/group in expt 
II). Statistical significance of  differences between groups was 
determined by t-test 
tivity [14]. Thus, it is important that we observe 
specific increases in 1,2-sn-DAG levels in CD liver 
(table 2) because only this stereoisomer can ac- 
tivate PKC. 
Accumulation of lipids was not homogeneous 
among liver cells. When, in preliminary ex- 
periments, we isolated hepatocytes from CD livers, 
we observed three populations of cells which dif- 
fered according to their sedimentation behavior in 
Krebs-Ringer buffer: one population (similar to 
that present in control ivers) sedimented readily; a 
second population sedimented slowly, and a third 
population (absent from control ivers) floated. It 
is possible that 1,2-sn-DAG concentrations in the 
floating cells were even higher than those observed 
in total homogenate. We conclude that choline 
deficiency was associated with a remarkable in- 
crease in hepatic 1,2-sn-DAG concentrations, 
reaching values higher than those occurring after 
stimulation of a receptor linked to phospholipase 
C activation (e.g. vasopressin receptor [10,15]) and 
of the order of magnitude needed to activate PKC 
in vitro [16]. The concentrations of 1,2-sn-DAG 
achieved in CD liver (table 2) were several-fold 
higher than the concentrations of exogenous 
1,2-sn-DAG used to activate PKC in platelets 
[17,18] or to modify responses to al-receptors in 
the liver [19]. We suggest that such elevations in 
1,2-sn-DAG concentrations could chronically 
stimulate PKC in vivo. 
Many studies have demonstrated that feeding a 
choline-devoid diet to experimental animals is car- 
cinogenic [20-30]. There are several mechanisms 
which have been suggested to explain this effect: 
increased cell death, increased cell proliferation, 
decreased DNA methylation, and increased lipid 
peroxidation. In the CD liver there is a progressive 
increase in cell proliferation, related to regenera- 
tion after parenchymal cell death [29,31]. Cell pro- 
liferation, with associated increased rate of DNA 
synthesis, could be the cause of greater sensitivity 
to chemical carcinogens [29]. Other stimuli for in- 
creased DNA synthesis are associated with car- 
cinogenesis: hepatectomy and necrogenic hemi- 
cals are examples [29]. However, Shinozuka et al. 
[30] found that the rate of cell proliferation could 
be dissociated from the rate at which preneoplastic 
lesions formed during choline deficiency, sug- 
gesting that cell proliferation was not the sole con- 
dition acting as a promoter of liver cancer. In- 
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terestingly, partial hepatectomy activates PKC in 
the liver [32,33] prior to DNA synthesis [33]. 
Methylation of DNA is important for the regula- 
tion of gene expression [34]. It has been suggested 
that the under-methylation f DNA (decreased 
5-methylcytosine content in nuclear DNA), observ- 
ed during choline deficiency, is responsible for car- 
cinogenesis [26]. Another proposed mechanism is 
based upon the observation of increased lipid 
peroxidation i  hepatic nuclei isolated from CD 
animals [35]. Lipid peroxides in the nucleus could 
be a source of free radicals which could modify 
DNA, and initiate tumor formation. 
The carcinogenic effects of tumor-promoting 
phorbol esters, as well as of several oncogenes have 
been linked to the activation of PKC [36]. For ex- 
ample, NIH 3T3 cells transformed with Ha-ras or 
Ki-ras, v-src, and v-fins oncogenes have elevated 
1,2-sn-DAG levels [37,38] as well as tonic activa- 
tion and partial down-regulation f PKC [37,38]. 
Activated PKC, in turn, may participate in 
mechanisms leading to the induction of expression 
of the c-myc oncogene [39,40]. We propose that 
the accumulation of 1,2-sn-DAG in CD liver may 
cause prolonged activation of PKC, thus acting as 
an endogenous tumor promoter. 
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